Holland - hollandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

intervet nederland b.v. - levend infectieus aviair bronchitisvirus - lyofilisaat voor suspensie - avian infectious bronchitis virus - kippen

Holland - hollandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

intervet nederland b.v. - levend infectieus aviair laryngotracheitisvirus - lyofilisaat voor suspensie voor injectie - avian infectious laryngotracheitis virus - niet eierleggende kippen

Den Europæiske Union - hollandsk - EMA (European Medicines Agency)

glaxosmithkline trading services - mepolizumab - astma - geneesmiddelen voor obstructieve aandoeningen van de luchtwegen, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa). hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.

Den Europæiske Union - hollandsk - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - teduglutide - malabsorptiesyndromen - andere maagdarmkanaal en metabolisme producten, - revestive is geïndiceerd voor de behandeling van patiënten van 1 jaar en ouder met short bowel syndrome (sbs). patiënten moeten stabiel zijn na een periode van darmaanpassing na de operatie. revestive is geïndiceerd voor de behandeling van patiënten in de leeftijd van 1 jaar en hoger met het short bowel syndroom. patiënten moeten stabiel zijn na een periode van darmaanpassing na de operatie.

Holland - hollandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

ceva sante animale b.v. - levend verzwakt aviaire infectieuze bronchitis virus serotype massachusetts, stam b-48 - lyofilisaat voor suspensie - avian infectious bronchitis virus - kippen

Holland - hollandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

intervet nederland b.v. - levend verzwakt mycoplasma synoviae vaccin, stam ms1 - lyofilisaat voor suspensie - levend verzwakt mycoplasma synoviae vaccin, stam ms1 6,5 - 8 e/dosis, - mycoplasma vaccine - legkippen

Holland - hollandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

ast farma b.v. - gentamicine - neusspray, oplossing - gentamicine 1,5 mg/ml, - gentamicin - honden; katten

Holland - hollandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

genera inc. - levend verzwakt aviaire infectieuze bursitis virusvaccin, stam vmg 91 - lyofilisaat voor suspensie - avian infectious bursal disease virus (gumboro disease) - kippen

Holland - hollandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

genera inc. - levend verzwakt aviaire infectieuze bursitis virusvaccin, stam vmg 91; natriumglutamaat (e 621) - lyofilisaat voor oraal gebruik - avian infectious bursal disease virus (gumboro disease) - kippen

Den Europæiske Union - hollandsk - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - varkens - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.